catalent.comHome - Catalent

Regional Sites China Japan Latin America Spanish Portuguese Oral Dose Development & Bioavailability Preclinical Development Formulation Bioavailability Enhancement Integrated Development Solutions Dose Form Design Better Treatments by Design Tablets & Capsules Orally Disintegrating Tablets Softgel Technology Packaging Solutions Oral Technologies Bioavailability Enhancement Modified/Controlled-Release Orally Disintegrating Tablets Abuse Deterrent Oral Macromolecule Delivery Softgel Technologies RP Scherer Softgel Technology Plant Based Softgel Technology Oral Macromolecule Delivery Abuse Deterrent Technology Smaller Easy to Swallow Softgels Oral Manufacturing Commercial Manufacturing Scale-Up & Product Launch Technology Transfers Oral Dose Analytical Solutions Solid State Screening Methods Development & Validation Stability Testing & Storage Biologics Biologics Development Gene Therapy Specialty Technologies Specialty Inhalation Metered Dose Inhalers Nebulized Blow-Fill-Seal Products Nasal Sprays Dry Powder Inhalers Ophthalmic Blow-Fill-Seal Development & Analytical Services Small Molecule Injectable Regulatory Support Services Clinical Supply Forecasting & Planning Packaging Services Comparator Sourcing Distribution & Logistics Consumer Over-The-Counter Nutritional Supplements Beauty Product Library Expert Content Biologics Clinical Supply Services Consumer Health Development & Bioavailability Dose Form Design Oral Technologies Softgel Technologies Oral Manufacturing Small Molecule Analytical Inhalation Ophthalmic Small Molecule Injectable Locations Asia Pacific Europe Latin America North America About Us Who We Are News & Events Our Leadership Our Scientists Investors Corporate Responsibility Diversity & Inclusion Careers Working at Catalent Why Join Us? Career Opportunities Select Page Regional Sites China Japan Latin America Spanish Portuguese Contact Us Contact Us Oral Dose Development & Bioavailability Preclinical Development Formulation Bioavailability Enhancement Integrated Development Solutions Dose Form Design Better Treatments by Design Tablets & Capsules Orally Disintegrating Tablets Softgel Technology Packaging Solutions Oral Technologies Bioavailability Enhancement Modified/Controlled-Release Orally Disintegrating Tablets Abuse Deterrent Oral Macromolecule Delivery Softgel Technologies RP Scherer Softgel Technology Plant Based Softgel Technology Oral Macromolecule Delivery Abuse Deterrent Technology Smaller Easy to Swallow Softgels Oral Manufacturing Commercial Manufacturing Scale-Up & Product Launch Technology Transfers Oral Dose Analytical Solutions Solid State Screening Methods Development & Validation Stability Testing & Storage Biologics Biologics Development Gene Therapy Specialty Technologies Specialty Inhalation Metered Dose Inhalers Nebulized Blow-Fill-Seal Products Nasal Sprays Dry Powder Inhalers Ophthalmic Blow-Fill-Seal Development & Analytical Services Small Molecule Injectable Regulatory Support Services Clinical Supply Forecasting & Planning Packaging Services Comparator Sourcing Distribution & Logistics Consumer Over-The-Counter Nutritional Supplements Beauty Product Library Expert Content Biologics Clinical Supply Services Consumer Health Development & Bioavailability Dose Form Design Oral Technologies Softgel Technologies Oral Manufacturing Small Molecule Analytical Inhalation Ophthalmic Small Molecule Injectable Locations Asia Pacific Europe Latin America North America About Us Who We Are News & Events Our Leadership Our Scientists Investors Corporate Responsibility Diversity & Inclusion Careers Working at Catalent Why Join Us? Career Opportunities CATALENT HAS ACQUIRED MASTHERCELL Enhancing capabilities in cell and gene therapy development and manufacturing to create a comprehensive solution for advanced biotherapeutics Learn More Catalent is the #1 partner in helping pharmaceutical, biotech and consumer health innovators develop, deliver and supply superior products that improve people’s lives. Play Video CATALENT ACQUIRES PREMIER EUROPEAN SITE FROM BRISTOL-MYERS SQUIBB Enhancing Biologics and Oral dose capabilities and capacity for product launch and commercial packaging Learn More Your Expert Partner in Gene Therapy Industry-leading expertise in adeno-associated viral vector (AAV) development and manufacturing Learn More Introducing OneBio SM Suite Accelerating timelines through integrated biologics development, manufacturing & supply Learn More CATALENT HAS ACQUIRED MASTHERCELL Enhancing capabilities in cell and gene therapy development and manufacturing to create a comprehensive solution for advanced biotherapeutics. Learn More Catalent is the #1 partner in helping pharmaceutical, biotech and consumer health innovators develop, deliver and supply superior products that improve people’s lives. Play Video CATALENT ACQUIRES PREMIER EUROPEAN SITE FROM BRISTOL-MYERS SQUIBB Enhancing Biologics and Oral dose capabilities and capacity for product launch and commercial packaging Learn More YOUR EXPERT PARTNER IN GENE THERAPY Industry-leading expertise in adeno-associated viral vector (AAV) development and manufacturing Learn More INTRODUCING ONEBIO SM SUITE Accelerating timelines through integrated biologics development, manufacturing & supply. Learn More How can we work together Oral Biologics Clinical Supply Consumer Latest News Perrigo and Catalent Announce FDA Approval of Perrigo’s AB-rated Generic Version of ProAir® HFA Gene Therapy With 40+ active gene therapy programs and leading expertise in Adeno Associate Viral (AAV) Vectors, Paragon Gene Therapy will provide you with full life cycle support of your life-saving therapeutic. Join Our Team Catalent is growing & hiring! Join the global drug development and delivery leader that puts “Patient First” at the center of our work every day. Learn more about careers at Catalent. Global Network With our broad range of experience and deep expertise, we have the talent and unique technologies to transform your concepts into excellent results. This is backed by our global reach, with facilities located worldwide enabling us to tailor a solution to fit your needs. See all of our locations NEWS Catalent Announces Supplying Blueprint Medicines’ Precision Therapy AYVAKIT™ (avapritinib) Perrigo and Catalent Announce FDA Approval of Perrigo’s AB-rated Generic Version of ProAir® HFA Catalent’s Senior Vice President & Chief Financial Officer, Wetteny Joseph, Inducted as a Member of the Executive Leadership Council Catalent to Host Workshop Demonstrating Advantages of Integrated Biologics Development Solutions in London, U.K. VIEW ALL NEWS EVENTS Complex Liquid Formulations: Solutions for Scale-Up Challenges CTS New England Drug Delivery Partnership Rapid Developability Assessment of Early Phase Molecules: Parallel Screening of Enabling Technologies and Use of PBPK Modeling VIEW ALL EVENTS EXPERT CONTENT Why do new Therapies Succeed or fail in the Marketplace? Elemental Impurities – Guidelines, Testing and Assessments Softgel Technology for Fast-Tracked Development Programs Flexible Manufacturing Strategies: What’s Best for your Product? VIEW ALL ARTICLES Follow Us. Share Us. Expert Content Subscribe Investors Careers Contact Us Site Map By using this website you understand and accept that Catalent tracks your website activities to be able to offer you a more tailored response or information to meet your requirements, and that your personal data will be held in accordance with our Privacy Policy | Privacy Shield Statement . Terms | Modern Slavery Statement Copyright 2020, Catalent, Inc - All Rights Reserved × × SIGN UP NOW TO STAY CURRENT WITH THE LATEST NEWS AND INSIGHTS SUBSCRIBE NOW SIGN UP NOW TO STAY CURRENT WITH THE LATEST NEWS AND INSIGHTS SUBSCRIBE NOW ×...